Verily Life Sciences and Samsung Electronics America announced today a collaboration bringing the Galaxy Watch 8 together with Verily’s precision health platform, Pre.

Samsung launched the Galaxy Watch 8 in July 2025, positioned as a consumer health tracker with AI features and a softer redesign. Now it’s got another life entirely.

Verily will fully integrate sensor data from Galaxy Watch and make it accessible in its Viewpoint Evidence solution, which is built on the Verily Pre platform and enables research sponsors to run real-world studies with re-contactable participant cohorts.

Millions of people bought the Watch 8 because they liked the thinness, the brighter display, or whatever marketing line worked. Now Verily can tap them for studies without building its own pipeline.

Sponsors will use Verily Pre data solutions, including Refinery for data harmonization and Workbench for analysis, modeling, and activation. Verily will also recruit Samsung users directly and manage participant engagement.

The companies will also explore potential joint development of new and enhanced end-to-end solutions for clinical research. If this works, expect future Galaxy Watches to ship with features designed for trials first and consumers second.

Verily has a long history of leading the design and verification of digital measures across various therapeutic areas, including Cardiometabolic, CNS, and Respiratory diseases, and the development of advanced AI algorithms for Parkinson’s.

“The use of consumer-friendly devices in clinical research makes it easier for participants to engage in studies, while enabling sponsors to use advanced biomarkers to generate high quality data,” said Scott Burke, Chief Technology Officer at Verily. “This collaboration realizes our vision to integrate health research into everyday life, in order to generate better evidence and make precision health possible for all.”

The post Samsung Galaxy Watch 8 enters clinical research era appeared first on Sammy Fans.